StockMarketWire.com - Renalytix AI, a developer of artificial intelligence-enabled diagnostics for kidney disease, said it had started a clinical validation study for its lead diagnostic product.

The product, KidneyIntelX, was designed to diagnose and improve clinical management of patients with Type II diabetes and those of African ancestry with fast-progressing kidney disease.

RenalytixAI said it expected to commercially launch KidneyIntelX as a laboratory developed test in its laboratory facilities to health systems and drug developers in the second half of 2019.


At 9:41am: [LON:RENX] share price was 0p at 120p



Story provided by StockMarketWire.com